SANTA CLARA, Calif.--(BUSINESS WIRE)--MedCI LLC, a life-science business consulting services company, announced the formation of a new strategic alliance with Genta Incorporated (OTCBB:GETA) to secure licensing partners for Genta’s small molecule oncology compound, tesetaxel. Tesetaxel is the leading oral taxane in clinical development and is a core component of Genta’s investigational drug portfolio. Under the agreement, MedCI will continue and extend current discussions with leading pharmaceutical companies in South Korea that focus on oncology.
